8-K: Envoy Medical Q3 2025: Debt Eliminated, Clinical Trial Advances

Envoy Medical reports a transformational third quarter, eliminating $32 million in debt, strengthening its balance sheet, and advancing its pivotal Acclaim cochlear implant clinical trial with FDA approval for the final stage.

Summary

• Eliminated over $32 million in debt without issuing new equity, substantially strengthening the balance sheet and materially improving Stockholders Equity.
• Received FDA approval to expand its pivotal Acclaim cochlear implant clinical trial to the final stage subsequent to quarter end, based on promising three-month data.
• Restarted enrollment in the pivotal clinical trial, with the first three patients enrolled in the final stage of the fully implanted investigational Acclaim cochlear implant.
• Successfully closed an up to $16 million registered direct offering post-quarter end to raise additional capital.
• Expanded its patent portfolio by securing additional global patents in the U.S., Europe, and Australia.
• Net revenue for the third quarter ended September 30, 2025, was $42 thousand, a decrease from $56 thousand in the prior year period.
• Research and development (R&D) expenses decreased by $57 thousand to $2.7 million for Q3 2025, primarily due to a shift from the development phase to the clinical trial phase.
• General and administrative (G&A) expenses increased by $752 thousand to $2.442 million for Q3 2025, mainly due to increased public company costs and expenses related to the September 2025 offering.
• Net loss for Q3 2025 was $6.482 million, compared to $5.960 million in Q3 2024.
• Cash balance was approximately $3.556 million as of September 30, 2025.

Sentiment

Score: 8

Explanation: The elimination of $32 million in debt and the FDA approval to advance the pivotal clinical trial to its final stage are transformative events that significantly de-risk the company and provide a clear path forward for its key product. While revenue declined and net loss increased, these operational and strategic achievements outweigh the short-term financial performance, indicating strong positive momentum.

Positives

• Eliminated over $32 million in debt without the issuance of new equity, substantially improving the balance sheet.
• Stockholders Equity materially improved as a result of the debt extinguishment.
• Received FDA approval to expand the pivotal Acclaim cochlear implant clinical trial to its final stage, a critical regulatory milestone.
• Restarted enrollment and successfully enrolled the first three patients in the final stage of the pivotal clinical trial.
• Successfully raised additional capital through an up to $16 million registered direct offering subsequent to quarter end.
• Expanded its patent portfolio by securing additional global patents in the U.S., Europe, and Australia.
• Achieved the three-month follow-up milestone in the clinical trial.
• Net cash used in operating activities decreased slightly to $12.516 million for the nine months ended September 30, 2025, from $12.858 million in the prior year.
• Net loss per share improved to $(0.35) in Q3 2025 from $(0.39) in Q3 2024, despite a higher net loss, indicating effective management of dilution relative to losses.

Negatives

• Net revenue decreased to $42 thousand in Q3 2025 from $56 thousand in Q3 2024.
• General and administrative expenses increased by $752 thousand, primarily due to increased public company costs and offering-related expenses.
• Operating loss increased to $(5.708) million in Q3 2025 from $(4.972) million in Q3 2024.
• Net loss increased to $(6.482) million in Q3 2025 from $(5.960) million in Q3 2024.
• Cash balance decreased to $3.556 million as of September 30, 2025, from $5.483 million at December 31, 2024.
• Total assets decreased to $8.181 million as of September 30, 2025, from $11.538 million at December 31, 2024.

Risks

• Changes in the market price of shares of Class A Common Stock.
• Changes in or removal of Envoy Medical's shares inclusion in any index.
• Success in retaining or recruiting, or changes required in, officers, key employees or directors.
• Unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products.
• Ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors.
• Disruptions in relationships with suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products.
• Changes in the need for capital and the availability of financing and capital to fund these needs.
• Changes in interest rates or rates of inflation.
• Legal, regulatory and other proceedings could be costly and time-consuming to defend.
• Changes in applicable laws or regulations, or the application thereof on Envoy Medical.
• A loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights.
• The effects of catastrophic events, including war, terrorism and other international conflicts.
• The fully implanted Acclaim Cochlear Implant is an investigational device, limited by Federal (or United States) law to investigational use.

Future Outlook

The company expects to increase momentum as it finishes 2025, driven by the expansion of its pivotal clinical trial and continued patient enrollment for the fully implanted Acclaim cochlear implant. It aims to expand its position as a first mover and market leader in fully implanted hearing solutions, continuing steady progress in its clinical trial and commercialization planning.

Management Comments

• "The third quarter was transformational for Envoy Medical as we continue to position ourselves to capitalize on the opportunity ahead of us."
• "We extinguished $32 million in debt without the issuance of new equity, substantially improving our balance sheet and eliminating the need to satisfy or service that debt in the future. As a result, our Stockholders Equity materially improved."
• "We continued to make steady progress in our pivotal clinical trial and believe we are on the right track."
• "Throughout the quarter, we received a number of additional global patents in the U.S., Europe, and Australia. We will continue to expand our position as a first mover and market leader in fully implanted hearing solutions."
• "Subsequent to quarter end, we achieved a major milestone as we received the critically important approval from the FDA to expand our pivotal clinical trial to its final stage."
• "We continue to see strong interest in our fully implanted cochlear implant trial as new patients are now rapidly enrolling in this trial."
• "I am very proud of the progress the Envoy Medical team is making, and we intend to increase our momentum as we finish 2025."

Industry Context

Envoy Medical operates in the hearing health industry, specifically pioneering fully implanted hearing solutions. Its focus on devices like the Acclaim CI, which leverages natural ear anatomy instead of a microphone, positions it as an innovator aiming to address severe to profound sensorineural hearing loss with a "first-of-its-kind" technology. The FDA Breakthrough Device Designation for Acclaim CI highlights its potential to significantly improve patient care compared to existing options. The company's strategy of expanding its patent portfolio reinforces its intent to secure a leading market position in this specialized niche.

Comparison to Industry Standards

• The Acclaim CI is highlighted as a "first-of-its-kind" hearing device, suggesting it aims to establish a new standard rather than directly compare to existing fully implanted cochlear implants, as there are no other fully implanted cochlear implants on the market.
• The Esteem FI-AMEI is noted as the "only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss," distinguishing it from other hearing aids or partially implanted devices.
• The company's approach of using a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound for the Acclaim CI represents a unique technological differentiation from traditional cochlear implants.
• The FDA Breakthrough Device Designation for the Acclaim CI in 2019 indicates regulatory recognition of its potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions compared to existing approved alternatives.

Related Party Transactions

• Accrued interest (related party) decreased from $703 thousand at December 31, 2024, to $0 at September 30, 2025.
• Term loans payable (related party) decreased from $18,716 thousand at December 31, 2024, to $0 at September 30, 2025.
• Operating lease right-of-use asset (related party) and operating lease liability (related party) are present on the balance sheet, indicating ongoing related party lease arrangements.
• Interest expense, related party was $(471) thousand for the three months ended September 30, 2025.
• Proceeds from the issuance of Term Loans (related party) was $10,000 thousand for the nine months ended September 30, 2025.
• Payment made for extinguishment of Term Loans (related party) was $(100) thousand for the nine months ended September 30, 2025.
• A deemed capital contribution associated with the extinguishment of Term Loans (related party) of $27,883 thousand was recorded.
• Modification of Term Loan Warrants (related party) amounted to $1,455 thousand.

Stakeholder Impact

• Shareholders: Significant positive impact due to debt elimination, balance sheet strengthening, and advancement of the pivotal clinical trial, which de-risks the company and provides a clearer path to commercialization for the Acclaim CI. The capital raise provides necessary funding.
• Patients: Potential for a new, innovative fully implanted cochlear implant (Acclaim CI) to address severe to profound sensorineural hearing loss, offering a "first-of-its-kind" solution.
• Employees: Continued progress in clinical trials and commercialization planning suggests stability and potential growth opportunities.
• Creditors: Debt elimination significantly reduces financial risk and improves the company's credit profile.

Next Steps

• Continue enrollment of new patients in the final stage of the pivotal clinical trial for the Acclaim cochlear implant.
• Increase momentum as the company finishes 2025.
• Advance commercialization planning for the Acclaim cochlear implant.
• Continue to expand the patent portfolio.
• Work towards PMA submission to the FDA for the Acclaim CI.

Key Dates

Recommendation

The elimination of $32 million in debt without equity dilution is a major de-risking event, substantially improving the company's financial health. Coupled with the critical FDA approval to advance the pivotal Acclaim cochlear implant clinical trial to its final stage and successful capital raising, the company has achieved significant milestones that position it for future growth and potential market leadership in fully implanted hearing solutions. These strategic and operational achievements far outweigh the short-term decline in revenue and increased net loss, indicating a strong positive trajectory for long-term investors.

Keywords

Hearing health, Cochlear implant, Medical device, FDA approval, Clinical trial, Balance sheet, Debt extinguishment, Patent portfolio, Acclaim CI, Esteem FI-AMEI, NASDAQ: COCH